|Table of Contents|

Progress of therapies for the advanced hepatocellular carcinoma

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

2017 10
Research Field:
Publishing date:


Progress of therapies for the advanced hepatocellular carcinoma
Zhang XiaoyuanHuang PengLi YanjingBai Yuxian
Harbin Medical University Cancer Hospital,Heilongjiang Harbin 150081,China.
hepatocellular carcinomatargeted agentchemotherapyimmunotherapy
The incidence of primary liver cancer continues to increase rapidly in recent years.Hepatocellular carcinoma (HCC) is the fifth most common cause of cancer and is the third leading cause of cancer death worldwide.The treatment of HCC is determined by the liver function,tumor size,metastasic pattern and the vascular invasion.Surgical resection and liver transplantation remain the only possibility for cure in HCC.Most patients lose the chance of topical treatment since they are already in advanced stage when they diagnosed.Systemic therapy is particularly important for patients with advanced HCC,including targeted agent,chemotherapy and immunotherapy.In this review,we discuss the current situation and progress of systemic therapies for the advanced HCC.


[1]McDermott U,Sharma SV,Dowell L,et al.Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling[J].USA:Proc Natl Acad Sci,2007,104:19936-19941.
[2]Llovet JM,Ricci S,Mazzaferro V,et al.Sorafenib in advanced hepatocellular carcinoma[J].N Engl J Med,2008,359:378-390.
[3]Cheng AL,Guan Z,Chen Z,et al.Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status:subset analyses of the phase III Sorafenib[J].Eur J Cancer,2012,48:1452-1465.
[4]Jelic S,Sotiropoulos GC.Hepatocellular carcinoma:ESMO Clinical Practice Guidelines for diagnosis,treatment and follow-up[J].Ann Oncol,2010,21(Suppl5):v59-64.
[5]Theysohn JM,Schlaak JF,Müller S,et al.Selective internal radiation therapy of hepatocellular carcinoma:Potential hepatopulmonary shunt reduction after sorafenib administration[J].J Vasc Interv Radiol,2012,23:949-952.
[6]Richly H,Schultheis B,Adamietz IA,et al.Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma:Results from a phase I extension trial[J].Eur J Can,2009,45:579-587.
[7]Ghassan K,Abou-Alfa,Donna Niedzwieski,et al.Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC):CALGB 80802 (Alliance) [J].J Clin Oncol,2016,1:21-23.
[8]Zhang YF,Wei W,Wang JH,et al.Transarterial chemoembolization combined with sorafenib for the treatment of hepatocellular carcinoma with hepatic vein tumor thrombus[J].Onco Targets and Therapy,2016,9:4239-4246.
[9]Wilhelm SM,Dumas J,Adnane L,et al.Regorafenib(BAY 73-4506):a new oral multikinase inhibitor of angiogenic,stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity[J].Int J Cancer,2011,129(1):245-255.
[10]Bruix J,Tak WY,Gasbarrini A,et al.Regorafenib as econdline therapy for intermediate or advanced hepatocellular carcinoma:Multicentre,open-label,phase Ⅱ safety study[J].Eur J Cancer,2013,49(16):3412-3419.
[11]Bruix J,Merle P,Granito A,et al.Efficacy and safety of regorafenib versus placebo in patients with hepatocellular carcinoma (HCC) progressing on sorafenib:results of the international,randomized phase 3 RESORCE trial[J].Ann Oncol,2016,27:140-141.
[12]Yeung KT,Cohen EE.Lenvatinib in advanced,radioactive iodine-refractory,differentiated thyroid carcinoma[J].Clin Cancer Res,2015,21:5420-5426.
[13]Chuma M,Terashita K,Sakamoto N.New molecularly targeted therapies against advanced hepatocellular carcinoma:from molecular pathogenesis to clinical trials and future directions[J].Hepatol Res,2015,45:E1-E11.
[14]Oikonomopoulos G,Aravind P,Sarker D.Lenvatinib:apotential breakthrough in advanced hepatocellular carcinoma [J]?Future Oncol,2016,12:465-476.
[15]Akanay-Diesel S,Hoff NP,Kürle S,et al.Sunitinib induced pyoderma gangrenosum-like ulcerations[J].Eur J Med Res,2011,16:491-494.
[16]Cheng AL,Kang YK,Lin DY,et al.Sunitinib versus sorafenib in advanced epatocellular cancer:Results of a randomized phase III trial[J].J Clin Oncol,2013,31:4067-4075.
[17]Bhide RS,Cai ZW,Zhang YZ,et al.Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-ol(BMS-540215),an in vivo active potent VEGFR-2 inhibitor[J].J Med Chem,2006,49:2143-2146.
[18]Park JW,Finn RS,Kim JS,et al.Phase II,open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma[J].Clin Cancer Res,2011,17:1973-1983.
[19]Johnson PJ,Qin S,Park JW,et al.Brivanib vs sorafenib as first-line therapy in patients with unresectable,advanced hepatocellular carcinoma:results from the randomized hase III BRISK-FL study[J].J Clin Oncol,2013,31:3517-3524.
[20]Llovet JM,Decaens T,Raoul JL,et al.Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed:results from the randomized phase III BRISK-PS study[J].J Clin Oncol,2013,31:3509-3516.
[21]Sciarrino E,Simonetti RG,Le Moli S,et al.Adriamycin treatment for hepatocellular carcinoma.Experience with 109 patients[J].Cancer,1985,56:2751-2755.
[22]Lai CL,Wu PC,Chan GC,et al.Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma.A prospective randomized trial[J].Cancer,1988,62:479-483.
[23]Fuchs CS,Clark JW,Ryan DP,et al.A phase II trial of gemcitabine in atients with advanced hepatocellular carcinoma[J].Cancer,2002,94:3186-3191.
[24]Patt YZ,Hassan MM,Aguayo A,et al.Oral capecitabine for the reatment of epatocellular carcinoma,cholangiocarcinoma,and gallbladder carcinoma[J].Cancer,2004,101:578-586.
[25]Qin S,Bai Y,Lim HY,et al.Randomized,multicenter,open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia[J].J Clin Oncol,2013,31:3501-3508.
[26]Leung TW,Patt YZ,Lau WY,et al.Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma[J].Clin Cancer Res,1999,5:1676-1681.
[27]Wang J,He XD,Yao N,et al.A meta-analysis of adjuvant therapy after potentially curative treatment for hepatocellular carcinoma[J].Can J Gastroenterol,2013,27:351-363.
[28]Giraudo L,Gammaitoni L,Cangemi M,et al.Cytokine-induced killer cells as immunotherapy for solid tumors:current evidences and perspectives[J].Immunotherapy,2015,7:999-1010.
[29]Wei F,Rong XX,Xie RY,et al.Cytokine-induced killer cells efficiently kill stem-like cancer cells of nasopharyngeal carcinoma via the NKG2D-ligands recognition[J].Oncotarget,2015,6:35023-35039.
[30]Li X,Dai D,Song X,et al.A meta-analysis of cytokine-induced killer cells therapy in combination with minimally invasive treatment for hepatocellular carcinoma[J].Clin Res Hepatol Gastroenterol,2014,38:583-591.
[31]Lee JH,Lim YS,Yeon JE,et al.Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma[J].Gastroenterology,2015,148:1383-1391.
[32]Chew V,Chen J,Lee D,et al.Chemokine-driven lymphocyte infiltration:an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma[J].Gut,2012,6:427-438.
[33]Ishiyama K,Ohdan H,Ohira M,et al.Difference in cytotoxicity against hepatocellular carcinoma between liver and periphery natural killer cells in humans[J].Hepatology,2006,43:362-372.
[34]Wu Y,Kuang DM,Pan WD,et al.Monocyte/macrophage-elicited natural killer cell dysfunction in hepatocellular carcinoma is mediated by CD48/2B4 interactions[J].Hepatology,2013,57:1107-1016.
[35]Wu J,Lanier LL.Natural killer cells and cancer[J].Adv Cancer Res,2003,90:127-156.
[36]Fu B,Tian Z,Wei H.Subsets of human natural killer cells and their regulatory effects[J].Immunology,2014,141:483-489.
[37]Pardoll DM.The blockade of immune checkpoints in cancer immunotherapy [J].Nat Rev Cancer,2012,12(4):252-264.
[38]Anthony B,El-Khoueiry.Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC)[R].ASCO,2013:CA209-240.
[39]Topalian SL,Hodi FS,Brahmer JR,et al.Safety,activity,and immune correlates of anti-PD-1 antibody in cancer[J].N Engl J Med,2012,366(26):2443-2454.
[40]Herbst RS,Soria JC,Kowanetz M,et al.Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients [J].Nature,2014,515(7528):563-567.


Last Update: 2017-04-01